These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24219000)

  • 1. K-Ras, intestinal homeostasis and colon cancer.
    Goel S; Huang J; Klampfer L
    Curr Clin Pharmacol; 2015; 10(1):73-81. PubMed ID: 24219000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.
    Haigis KM; Kendall KR; Wang Y; Cheung A; Haigis MC; Glickman JN; Niwa-Kawakita M; Sweet-Cordero A; Sebolt-Leopold J; Shannon KM; Settleman J; Giovannini M; Jacks T
    Nat Genet; 2008 May; 40(5):600-8. PubMed ID: 18372904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.
    Zhao C; Xiao H; Wu X; Li C; Liang G; Yang S; Lin J
    Oncotarget; 2015 Jun; 6(16):14472-87. PubMed ID: 25961376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
    Serova M; Astorgues-Xerri L; Bieche I; Albert S; Vidaud M; Benhadji KA; Emami S; Vidaud D; Hammel P; Theou-Anton N; Gespach C; Faivre S; Raymond E
    Mol Cancer Ther; 2010 May; 9(5):1308-17. PubMed ID: 20406951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis.
    Basu Roy UK; Henkhaus RS; Loupakis F; Cremolini C; Gerner EW; Ignatenko NA
    Int J Cancer; 2013 Jul; 133(1):43-57. PubMed ID: 23280667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a novel oncogenic K-ras mutation in colon cancer.
    Akagi K; Uchibori R; Yamaguchi K; Kurosawa K; Tanaka Y; Kozu T
    Biochem Biophys Res Commun; 2007 Jan; 352(3):728-32. PubMed ID: 17150185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
    Linardou H; Dahabreh IJ; Kanaloupiti D; Siannis F; Bafaloukos D; Kosmidis P; Papadimitriou CA; Murray S
    Lancet Oncol; 2008 Oct; 9(10):962-72. PubMed ID: 18804418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).
    Nemunaitis J; Cox J; Meyer W; Courtney A; Mues G
    Am J Clin Oncol; 1997 Oct; 20(5):527-9. PubMed ID: 9345343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of occult metastases in sentinel lymph nodes from colon cancer patients by K-ras mutation peptide nucleic acid clamp PCR.
    Oltedal S; Gilje B; Kørner H; Aasprong OG; Tjensvoll K; Heikkilä R; Smaaland R; Nordgård O
    Ann Surg; 2010 Jun; 251(6):1087-91. PubMed ID: 20485143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of K-ras mutations with p16 methylation in human colon cancer.
    Guan RJ; Fu Y; Holt PR; Pardee AB
    Gastroenterology; 1999 May; 116(5):1063-71. PubMed ID: 10220498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer.
    Miyakura Y; Sugano K; Fukayama N; Konishi F; Nagai H
    Jpn J Clin Oncol; 2002 Jun; 32(6):219-21. PubMed ID: 12110640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway.
    Weickhardt AJ; Tebbutt NC; Mariadason JM
    Curr Cancer Drug Targets; 2010 Dec; 10(8):824-33. PubMed ID: 20718704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516).
    Nemunaitis J; Cox J; Hays S; Meyer W; Kebart R; Ognoskie N; Courtney A; Yu Y; Rasmussen H; Tong A
    Cancer Invest; 2000; 18(3):185-90. PubMed ID: 10754986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation.
    Luo F; Ye H; Hamoudi R; Dong G; Zhang W; Patek CE; Poulogiannis G; Arends MJ
    J Pathol; 2010 Apr; 220(5):542-50. PubMed ID: 20087880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. K-ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma.
    Mannan A; Hahn-Strömberg V
    APMIS; 2012 Jun; 120(6):459-68. PubMed ID: 22583358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ras gene activation and epidermal growth factor receptor expression in human colon cancer.
    Ravikumar TS; Wolf B; Cocchiaro C; D'Emilia J; Steele G
    J Surg Res; 1989 Nov; 47(5):418-22. PubMed ID: 2682005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K-ras gene mutation as an early prognostic marker of colon cancer.
    Szpon Ł; Stal A; Zawadzki M; Lis-Nawara A; Kielan W; Grzebieniak Z
    Pol Przegl Chir; 2016 Jan; 88(1):15-9. PubMed ID: 27096769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
    Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.